EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Intratumoral Abundance of M2-Macrophages is Associated With Unfavorable Prognosis and Markers of T-Cell Exhaustion in Small Cell Lung Cancer Patients

Sebastian Klein, Annalena Schulte, Christoph Arolt, Yuri Tolkach, Hans Christian Reinhardt, Reinhard Buettner, Alexander Quaas

Modern Pathology · 2023-10 · 36 (10) · 100272

DOI: 10.1016/j.modpat.2023.100272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2023-10. Verfasst von Sebastian Klein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Pathology and Neuropathology, University Hospital and Medical Faculty Cologne, and Center for Molecular Medicine, Cologne, Germany; Dep…. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma, Biomarkers, Tumor, Macrophages. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Astellas Pharma US, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small cell lung cancer (SCLC) accounts for about 10% to 15% of lung cancer cases. Unlike non-SCLC, therapy options for SCLC are limited, reflected by a 5-year survival rate of about 7%. At the same time, the rise of immunotherapeutic approaches in cancer therapy has rationalized to account for inflammatory phenotypes in tumors. However, the composition of the inflammatory microenvironment in human SCLC is poorly understood to date. In our study, we used in-depth image analysis of virtual whole-slide-images of 45 SCLC tumors and evaluated different markers of M2-macrophages (CD163 and CD204) together with global immunologic markers (CD4, CD8, CD68, CD38, FOXP3, and CD20) and characterized their abundance intratumorally using quantitative image analysis, combined with a deep-learning model for tumor segmentation. In addition, independent scoring, blinded to the results of the computational analysis, was performed by an expert pathologist (A.Q.) of both CD163/CD204 and PD-L1. To this end, we evaluated the prognostic relevance of the abundance of these cell types to overall survival. Given a 2-tier threshold of the median of the M2 marker CD163 within the study population, there was a 12-month overall survival rate of 22% (95% CI, 10%-47%) for patients with high CD163 abundance and 41% (95% CI, 25%-68%) for patients with low CD163 counts. Patients with increased CD163 had a median overall survival of 3 months compared to 8.34 months for patients with decreased CD163 counts (P = .039), which could be confirmed by an expert pathologist (A.Q., P = .018). By analyzing cases with increased CD163 cell infiltrates, a trend for higher FOXP3 counts and PD-L1 positive cells, together with increased CD8 T-cell infiltrates, was observed, which could be confirmed using an independent cohort at the transcriptional level. Together, we showed that markers of M2 were associated with unfavorable outcome in our study cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsSmall Cell Lung CarcinomaBiomarkers, TumorMacrophagesLymphocytes, Tumor-InfiltratingTumor-Associated MacrophagesT-LymphocytesHumansMaleFemaleMiddle AgedAgedPrognosisTumor MicroenvironmentAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenAged, 80 and overReceptors, Cell SurfaceAdultT-Cell Exhaustion

Stichwörter der Autor:innen

CD163M2SCLCTMEbiomarkerlung cancermacrophagessmall cell lung cancertumor microenvironment

Substanzen

Biomarkers, TumorAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenReceptors, Cell Surface

Autor:innen und Institutionen

  • Institute for Pathology and Neuropathology, University Hospital and Medical Faculty Cologne, and Center for Molecular Medicine, Cologne, Germany; Department of Hematology and Stem Cell Transplantation, University Duisbu…
  • Institute for Pathology and Neuropathology, University Hospital and Medical Faculty Cologne, and Center for Molecular Medicine, Cologne, Germany.
  • Department of Hematology and Stem Cell Transplantation, University Duisburg-Essen, University Hospital Essen, Essen, Germany; West German Cancer Center Network, Partner Site Essen, Essen, Germany; German Cancer Consorti…

Förderung

  • Deutsche Forschungsgemeinschaft
  • Astellas Pharma US
  • AstraZeneca

Zitieren

APA

Klein, S., Schulte, A., Arolt, C., Tolkach, Y., Reinhardt, H. C., Buettner, R., & Quaas, A. (2023). Intratumoral Abundance of M2-Macrophages is Associated With Unfavorable Prognosis and Markers of T-Cell Exhaustion in Small Cell Lung Cancer Patients. Modern Pathology, 36(10), 100272. https://doi.org/10.1016/j.modpat.2023.100272

Vancouver

Klein S, Schulte A, Arolt C, Tolkach Y, Reinhardt HC, Buettner R, et al. Intratumoral Abundance of M2-Macrophages is Associated With Unfavorable Prognosis and Markers of T-Cell Exhaustion in Small Cell Lung Cancer Patients. Modern Pathology. 2023;36(10):100272. doi:10.1016/j.modpat.2023.100272

BibTeX
@article{Klein2023,
  author = {Klein, Sebastian and Schulte, Annalena and Arolt, Christoph and Tolkach, Yuri and Reinhardt, Hans Christian and Buettner, Reinhard and Quaas, Alexander},
  title = {Intratumoral Abundance of M2-Macrophages is Associated With Unfavorable Prognosis and Markers of T-Cell Exhaustion in Small Cell Lung Cancer Patients},
  journal = {Modern Pathology},
  year = {2023},
  volume = {36},
  number = {10},
  pages = {100272},
  doi = {10.1016/j.modpat.2023.100272}
}
Kostenlos starten →